These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23579861)

  • 1. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
    Guijarro-Muñoz I; Sánchez A; Martínez-Martínez E; García JM; Salas C; Provencio M; Alvarez-Vallina L; Sanz L
    Med Oncol; 2013; 30(2):572. PubMed ID: 23579861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
    Vincenzi B; Zoccoli A; Schiavon G; Iuliani M; Pantano F; Dell'aquila E; Ratta R; Muda AO; Perrone G; Brunelli C; Correale P; Riva E; Russo A; Loupakis F; Falcone A; Santini D; Tonini G
    Eur J Cancer; 2013 Apr; 49(6):1501-8. PubMed ID: 23266047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
    Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
    Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
    Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
    Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
    Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
    BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    Pohl A; El-Khoueiry A; Yang D; Zhang W; Lurje G; Ning Y; Winder T; Hu-Lieskoven S; Iqbal S; Danenberg KD; Kahn M; Teo JL; Shriki J; Stebbing J; Lenz HJ
    Pharmacogenomics J; 2013 Apr; 13(2):173-80. PubMed ID: 22231565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
    PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.
    Zuurbier L; Rahman A; Cordes M; Scheick J; Wong TJ; Rustenburg F; Joseph JC; Dynoodt P; Casey R; Drillenburg P; Gerhards M; Barat A; Klinger R; Fender B; O'Connor DP; Betge J; Ebert MP; Gaiser T; Prehn JHM; Griffioen AW; van Grieken NCT; Ylstra B; Byrne AT; van der Flier LG; Gallagher WM; Postel R
    Oncotarget; 2017 Jun; 8(26):42949-42961. PubMed ID: 28487489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
    Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
    Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.
    Goede V; Coutelle O; Neuneier J; Reinacher-Schick A; Schnell R; Koslowsky TC; Weihrauch MR; Cremer B; Kashkar H; Odenthal M; Augustin HG; Schmiegel W; Hallek M; Hacker UT
    Br J Cancer; 2010 Oct; 103(9):1407-14. PubMed ID: 20924372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy.
    Kara O; Duman BB; Kara B; Erdogan S; Parsak CK; Sakman G
    Asian Pac J Cancer Prev; 2012; 13(12):6397-401. PubMed ID: 23464465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
    Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
    Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.
    Marien KM; Croons V; Martinet W; De Loof H; Ung C; Waelput W; Scherer SJ; Kockx MM; De Meyer GR
    Expert Rev Mol Diagn; 2015 Mar; 15(3):399-414. PubMed ID: 25585649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.